Clinical Trial: Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease
Brief Summary: Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. This study will assess the long-term safety and efficacy of pasireotide in patients with Cushing's disease.
Detailed Summary:
Sponsor: Novartis Pharmaceuticals
Current Primary Outcome: Long term efficacy (UFC) in patients with Cushing's disease [ Time Frame: at the end of the study ]
Original Primary Outcome:
Current Secondary Outcome:
- Long term safety [ Time Frame: at the end of the study ]
- Tolerability [ Time Frame: at the end of the study ]
- Pharmacokinetics [ Time Frame: at the end of the study ]
- Development of biomarker [ Time Frame: at the end of the study ]
Original Secondary Outcome:
Information By: Novartis
Dates:
Date Received: September 13, 2005
Date Started: August 2004
Date Completion:
Last Updated: November 15, 2016
Last Verified: November 2016